Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel Free SLXNW Stock Alerts

Silexion Therapeutics Corp - Warrant (SLXNW) Competitors

$0.01 0.00 (0.00%)
As of 09/11/2026
Compare

SLXNW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Silexion Therapeutics Corp - Warrant stock or one of its competitors? Silexion Therapeutics Corp - Warrant's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silexion Therapeutics Corp - Warrant compare to Alvotech?

Silexion Therapeutics Corp - Warrant (NASDAQ:SLXNW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Silexion Therapeutics Corp - WarrantN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, Silexion Therapeutics Corp - Warrant and Silexion Therapeutics Corp - Warrant both had 1 articles in the media. Silexion Therapeutics Corp - Warrant's average media sentiment score of 1.89 beat Alvotech's score of 1.87 indicating that Silexion Therapeutics Corp - Warrant is being referred to more favorably in the media.

Company Overall Sentiment
Silexion Therapeutics Corp - Warrant Very Positive
Alvotech Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silexion Therapeutics Corp - WarrantN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Summary

Silexion Therapeutics Corp - Warrant and Alvotech tied by winning 1 of the 2 factors compared between the two stocks.

How does Silexion Therapeutics Corp - Warrant compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Silexion Therapeutics Corp - Warrant (NASDAQ:SLXNW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Silexion Therapeutics Corp - WarrantN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Silexion Therapeutics Corp - Warrant N/A N/A N/A

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 1.89 equaled Silexion Therapeutics Corp - Warrant'saverage media sentiment score.

Company Overall Sentiment
Apollomics Very Positive
Silexion Therapeutics Corp - Warrant Very Positive

Summary

Apollomics beats Silexion Therapeutics Corp - Warrant on 1 of the 1 factors compared between the two stocks.

How does Silexion Therapeutics Corp - Warrant compare to Aravive?

Silexion Therapeutics Corp - Warrant (NASDAQ:SLXNW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Silexion Therapeutics Corp - WarrantN/A N/A N/A
Aravive N/A N/A N/A

In the previous week, Silexion Therapeutics Corp - Warrant had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Silexion Therapeutics Corp - Warrant and 0 mentions for Aravive. Silexion Therapeutics Corp - Warrant's average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Silexion Therapeutics Corp - Warrant is being referred to more favorably in the media.

Company Overall Sentiment
Silexion Therapeutics Corp - Warrant Very Positive
Aravive Neutral

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silexion Therapeutics Corp - WarrantN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Silexion Therapeutics Corp - Warrant and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Silexion Therapeutics Corp - Warrant compare to bioAffinity Technologies?

Silexion Therapeutics Corp - Warrant (NASDAQ:SLXNW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silexion Therapeutics Corp - WarrantN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Silexion Therapeutics Corp - WarrantN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

In the previous week, Silexion Therapeutics Corp - Warrant and Silexion Therapeutics Corp - Warrant both had 1 articles in the media. Silexion Therapeutics Corp - Warrant's average media sentiment score of 1.89 equaled bioAffinity Technologies'average media sentiment score.

Company Overall Sentiment
Silexion Therapeutics Corp - Warrant Very Positive
bioAffinity Technologies Very Positive

Summary

bioAffinity Technologies beats Silexion Therapeutics Corp - Warrant on 1 of the 1 factors compared between the two stocks.

How does Silexion Therapeutics Corp - Warrant compare to BioVie?

Silexion Therapeutics Corp - Warrant (NASDAQ:SLXNW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

In the previous week, BioVie had 1 more articles in the media than Silexion Therapeutics Corp - Warrant. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Silexion Therapeutics Corp - Warrant. Silexion Therapeutics Corp - Warrant's average media sentiment score of 1.89 beat BioVie's score of 0.94 indicating that Silexion Therapeutics Corp - Warrant is being referred to more favorably in the media.

Company Overall Sentiment
Silexion Therapeutics Corp - Warrant Very Positive
BioVie Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silexion Therapeutics Corp - WarrantN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Silexion Therapeutics Corp - WarrantN/A N/A N/A
BioVie N/A N/A N/A

Summary

Silexion Therapeutics Corp - Warrant and BioVie tied by winning 1 of the 2 factors compared between the two stocks.

Get Silexion Therapeutics Corp - Warrant News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLXNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLXNW vs. The Competition

Export
MetricSilexion Therapeutics Corp - WarrantBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.86B$7.17B$12.73B
Dividend YieldN/A3.63%2.56%11.15%
P/E RatioN/A14.18273.8225.29
Price / SalesN/A1,486.37656.5399.10
Price / CashN/A106.6877.0451.44
Price / BookN/A15.1210.336.20
Net IncomeN/A-$22.86M$3.50B$358.50M
7 Day PerformanceN/A-4.32%-3.33%-2.35%
1 Month PerformanceN/A-0.01%-0.42%-2.77%
1 Year PerformanceN/A40.62%19.21%7.64%

Silexion Therapeutics Corp - Warrant Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLXNW
Silexion Therapeutics Corp - Warrant
N/A$0.01
flat		N/A-72.2%$0.00N/AN/AN/A
ALVOW
Alvotech
N/A$0.30
flat		N/AN/A$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-13.0%		N/A-23.6%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.24
-56.7%		N/A+237.2%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SLXNW) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
17 Nobel Prize winners… one startling warning
On July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...
Porter & Company | Sponsoredtc pixel